NEW YORK (GenomeWeb) – Philips recently introduced an assay service called OncoSignal that the firm claims can determine pathway activity in various cancers, providing information that can be used to guide therapy selection.

The Dutch multinational is now on track to introduce a kitted version of the assay, which can be run on standard quantitative PCR equipment, by the end of the year, according to Jos Rijntjes, head of commercial operations at Philips Molecular Pathway Diagnostics.